- Home
- DOX vs JAZZ Comparison
DOX vs JAZZ Comparison
Compare DOX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOX
- JAZZ
- Stock Information
- Founded
- DOX 1982
- JAZZ 2003
- Country
- DOX United States
- JAZZ Ireland
- Employees
- DOX N/A
- JAZZ N/A
- Industry
- DOX EDP Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- DOX Technology
- JAZZ Health Care
- Exchange
- DOX Nasdaq
- JAZZ Nasdaq
- Market Cap
- DOX 9.5B
- JAZZ 7.9B
- IPO Year
- DOX 1998
- JAZZ 2007
- Fundamental
- Price
- DOX $82.29
- JAZZ $137.57
- Analyst Decision
- DOX Buy
- JAZZ Strong Buy
- Analyst Count
- DOX 3
- JAZZ 14
- Target Price
- DOX $108.00
- JAZZ $179.21
- AVG Volume (30 Days)
- DOX 831.1K
- JAZZ 739.1K
- Earning Date
- DOX 11-11-2025
- JAZZ 11-05-2025
- Dividend Yield
- DOX 2.56%
- JAZZ N/A
- EPS Growth
- DOX 13.12
- JAZZ N/A
- EPS
- DOX 4.90
- JAZZ N/A
- Revenue
- DOX $4,646,577,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- DOX N/A
- JAZZ $5.70
- Revenue Next Year
- DOX $4.11
- JAZZ $6.16
- P/E Ratio
- DOX $16.79
- JAZZ N/A
- Revenue Growth
- DOX N/A
- JAZZ 4.52
- 52 Week Low
- DOX $78.61
- JAZZ $95.49
- 52 Week High
- DOX $95.41
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- DOX 43.00
- JAZZ 67.32
- Support Level
- DOX $80.74
- JAZZ $125.79
- Resistance Level
- DOX $82.91
- JAZZ $140.39
- Average True Range (ATR)
- DOX 1.30
- JAZZ 3.30
- MACD
- DOX 0.03
- JAZZ 0.70
- Stochastic Oscillator
- DOX 38.64
- JAZZ 82.33
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.